When we studied the merits of aminoglutethimide for the treatment of metastatic breast cancer in postmenopausal women in a phase II clinical trial we were confronted with an incidence of manifest myxedema in 25% and of subclinical hypothyroidism, still compensated by a rise of serum thyrotropin (TSH) in 78% of the patients after 8 weeks (Bruning et al., 1984). This relatively high incidence of diminished thyroid function seemed to be related to a relatively high frequency of elevated pretreatment TSH levels in our study population.
When we studied the merits of aminoglutethimide for the treatment of metastatic breast cancer in postmenopausal women in a phase II clinical trial we were confronted with an incidence of manifest myxedema in 25% and of subclinical hypothyroidism, still compensated by a rise of serum thyrotropin (TSH) in 78% of the patients after 8 weeks (Bruning et al., 1984) . This relatively high incidence of diminished thyroid function seemed to be related to a relatively high frequency of elevated pretreatment TSH levels in our study population.
In this report we present evidence that postoperative irradiation of supraclavicular lymph nodes in postmenopausal breast cancer patients may frequently lead to subclinical thyroid dysfunction although the irradiation comprises only a minor part of the thyroid. This finding explains why a drug like aminoglutethimide by a further decrement of thyroid hormone synthesis (Studer et al., 1970; Gower, 1974) (Fletcher et al., 1980) . It seemed reasonable to assume that in both groups a minor part of the thyroid could have received direct irradiation. The fields of irradiation are shown in Figure 1 (Keuls, 1952 unlikely also that breast cancer itself is associated with primary hypothyroidism, as no significant differences were found between the non-irradiated breast cancer group III and the control patients with endometrial or colorectal cancer (group IV and V). Although an increased incidence of hypothyroidism has been reported in breast cancer patients (Mittra & Hayward, 1974; Rose & Davies, 1978; Thomas et al., 1983) other workers have not observed such an association (Schottenfield, 1968; Hedley et al., 1981) . Radiotherapy involving the thyroid region for head and neck cancer (Shafer et al., 1975; Posner et al., 1984) or Hodgkin's disease (Schimpff et al., 1980; Smith et al., 1981; Peden et al., 1982) has been reported to be followed by an increased incidence of mostly subclinical hypothyroidism. In these cases the whole thyroid was generally irradiated with cumulative doses ranging from 40 to 70Gy. In our breast cancer patients the postoperative irradiation could only comprise a minor fraction of the total thyroid gland, i.e. the lower part of the ipsilateral lobe and the isthmus. Yet this appeared to be sufficient to cause a significantly increased occurrence of elevated TSH levels. The much more sensitive TSH rise after administration of thyrotropin releasing hormone would probably have revealed an even greater occurrence of diminished thyroid function. The present data do not indicate a consistent pattern of autoantibodies against thyroid which might explain the results after damaging only part of the thyroid by radiation directly. This is in agreement with observation by others (Schimpff et al., 1980; Holten, 1983) .
Treatment with 131J jas been demonstrated to be associated with the development of thyroid antibodies, i.e. predominantly microsomal antibodies (Lundell & Johnson, 1973) . However, characteristics of the thyroid irradiation by 131J are quite different from those of external radiotherapy.
Moreover patients treated with 131J invariably had thyroid disease, which more frequently entails the generation of autoantibodies. Thyroid antibodies occur in apparently healthy individuals, especially females and more frequently with increasing age. The sparse occurrence of thyroid antibodies in our patients, therefore, is no good evidence for an autoimmune reaction to radiation damage to the thyroid. Other tests may be necessary to reveal the possible induction of autoimmune thyroiditis. Direct radiation damage, be it to only a minor part of the thyroid may just add to the progressive decrement of function which is often present in postmenopausal women. In the same way aminoglutethimide may contribute to a condition which becomes clinically manifest as myxedema.
The drug's action is known to involve competitive inhibition at the mitochondrial P450 cytochrome level. In this way it interferes with hydroxylation steps required for the formation of various steroid hormones such as cortisol and aldosterone or the precursors of estrone and estradiol (Santen et al., 1982) . Hydroxylation steps normally needed for iodination involved in the synthesis of thyroid hormones may also be hampered to an extent which leads to clinically manifest hypothyroidism.
In our previous study (Bruning et al., 1984) we observed that 17 out of 32 patients entered into a phase II clinical trial of aminoglutethimide 1000mg plus hydrocortisone 40mg daily for advanced postmenopausal breast cancer had elevated serum TSH levels before treatment. Of these 17 patients 11 had received irradiation on supraclavicular lymph nodes in the past. Only 7 of the 15 patients with normal pretreatment levels of TSH had been treated similarly. After 8 weeks of aminoglutethimide therapy 5 additional patients had elevated TSH values, one of them without previous irradiation. All but 2 patients with elevated pretreatment values of serum TSH showed a further increase at 8 weeks, 7 of them developing clinically manifest hypothyroidism with decreased free thyroxine index values. The difference in occurrence of hypothyroidism which was observed by Santen (1980) as sporadic and by ourselves as rather frequent, can readily be explained by the infrequent use of postoperative irradiation of supraclavicular lymph nodes in the American breast cancer patients (R.J. Santen, personal communication) . Clinicians treating elderly women with cytochrome P450 inhibiting drugs like aminoglutethimide should be aware of the possible deterioration of thyroid function especially when the organ has been irradiated in the past.
